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Abstract 
Tuberculosis vaccine candidates are entering clinical studies in areas where BCG fails. 
This is a high risk strategy. We suggest that geographical variation in the efficacy of 
BCG is related to the presence in developing countries of a cross-reactive background 
Th2-like response, probably attributable to exposure of mother and infant to helminths 
and environmental mycobacteria. Such Th2-like activity can stop M. tuberculosis from 
being pushed into a latent state by the Th1 response, impair bactericidal functions and 
cause toxicity of TNF-α and pulmonary fibrosis. A successful vaccine, rather than 
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1. Introduction 
1.1 Immunity to TB; the paradox 
Immunity to M. tuberculosis requires a Th1 response. Genetic defects in IL-12 or IFN-γ pathways 
lead to susceptibility [1]. However M. tuberculosis rapidly evokes a potent Th1 response, even in 
those animals or humans who then go on to get the disease. For instance release of IFN-γ in 
response to ESAT-6 is often used as a test for exposure and becomes positive very rapidly [2]. So 
why do certain people get tuberculosis?  A fashionable hypothesis in 2004 would be that the 
patient has excessive immunoregulatory activity that is suppressing the protective response. 
Interestingly some patients have very high levels of IL-10 and appear essentially anergic. This 
does suggest excessive activity of some kind of regulatory T cell. However most patients, far 
from being anergic, have the necrotising response originally defined by Robert Koch in guinea 
pigs and subsequently observed in man [3]. This suggests that the relative activity of the 
regulatory pathways is variable in TB, but whether this activity is high or low, the patient still has 
the disease. The activity of regulatory T cells might not therefore be the crucial factor. It seems 
increasingly likely that M. tuberculosis is pathogenic not because it fails to evoke a Th1 response, 
or causes downregulation of that response, but rather because it evokes a “deliberately” corrupted 
Th1 response that cannot control the organism and leads instead to immunopathology. 
 
1.2. Pathogenicity; failure to evoke Th1, or deliberate sabotage ? 
It has been apparent since the time of Robert Koch that the response elicited by M. tuberculosis 
can cause tissue necrosis without killing the bacteria. Similarly the failure of the host immune 
system to eliminate residual organisms, even after the vast majority have been killed by 
chemotherapy is a constant paradox and problem, leading to the requirement for 6 months of 
therapy. The fact that the Koch phenomenon is not protective, and can lead to susceptibility that 
is greater than that of un-immunised controls, was conclusively demonstrated by many workers 
in the early decades of the 20th century [4].  More recently studies of pulmonary infection in the 
Balb/c mouse have led to the observation that after an initial phase of relatively pure Th1 
response, which temporarily stops replication of the organisms, the disease progresses again 
when IL-4 starts to be expressed [5]. Moreover TNF-α became toxic to the animals at the same 
time. Several other experimental models of infection have also found that toxicity of TNF-α can 
be associated with the presence of IL-4 in a dominantly Th1-mediated site of inflammation. We 
have reviewed these data, and the likely mechanisms elsewhere [6].  Subsequent reports noted 4 
that the presence of IL-4 is not merely a late consequence of progressive infection. In fact if a 
Th2 response to M. tuberculosis, even to a single epitope expressed within the organism, is 
evoked before challenge with virulent organisms, the subsequent disease is enhanced, particularly 
immunopathology, weight loss and fibrosis [7]. Since these are important but neglected 
characteristics of the human disease, we investigated IL-4 KO Balb/c mice, and confirmed that in 
the absence of functional IL-4 genes, the infection was somewhat attenuated, but more 
importantly, the toxicity of TNF-α eliminated and fibrosis diminished [8].  The latter is 
interesting because there is a view that Th2 cytokines are needed for human pulmonary fibrosis, 
which is striking in TB, whereas IFN-γ downregulates fibrosis [9]. These effects will not be 
apparent in mouse strains where IL-4 is not induced during progressive disease, and most are 
probably not mediated via STAT-6 [10]. The “non-Th2” effects of IL-4 are signalled via IRS-1 
and IRS-2.  
 
2.  The situation in man 
2.1. IL-4 in human tuberculosis 
Are these findings in Balb/c mice relevant to man, or is human tuberculosis is more like that 
occurring in some other mouse strain? Is IL-4 a feature of human tuberculosis?  We have 
summarised the mass of data elsewhere [6]. Briefly, TB patients have IL-4-dependent IgE and 
IgG4 antibody, T cells in the blood that secrete IL-4 in response to Mycobacterium tuberculosis 
antigens, multiple serological markers of IL-4 activity (such as soluble CD30), both CD4 and 
CD8 cells that secrete IL-4 in vitro as detected by flow cytometry, IL-4 in lesions by in situ 
hybridisation, increased IL-4 mRNA by qRT-PCR, even using unstimulated fresh peripheral 
blood mononuclear cells, and in some instances, free IL-4 in serum at levels that can be measured 
by ELISA. (Regional differences in the quantity of IL-4 present in TB patients are discussed 
later). 
 
2.2. IL-4, susceptibility  and immunopathology in man 
Why might IL-4 be critically important in human tuberculosis? IL-4 deactivates macrophages, 
switches off signalling via TLR-2 and potently downregulates iNOS [11], which may play a 
crucial role in driving M. tuberculosis into latency [12]. A recent study has revealed that 
apparently healthy health-care workers whose CD8+ T cells made IL-4 in response to M. 
tuberculosis, went on to develop active disease within 2-4 years [13]. So IL-4 might undermine 5 
resistance in the early stages of disease. However it might also contribute to immunopathology, 
as in the Balb/c mouse. The presence of IL-4 in peripheral blood cells, whether detected by qRT-
PCR, or detected by flow cytometry after stimulation with PMA and calcium ionophore, 
correlates with cavitary disease [14, 15]. Moreover, using bronchoalveolar lavage samples to look 
at the cytokine profile of lymphocytes infiltrating the lungs, the % of IL-4-secreting cells 
averaged 14% in samples from cavitary disease, but only 2-3 % in samples for non-cavitary 
disease [16]. This leads to the possibility that as in the mouse, the presence of IL-4 contributes to 
immunopathology within the dominantly Th1-mediated lesions. The IL-4 hypothesis therefore 
explains the well-known switch in the role of TNF-α from protective to toxic as the disease 
progresses [17], and the presence of fibrosis in dominantly Th1 lesions [8, 9]. 
 
2.3. The role of IL-4δ2, an antagonist of IL-4 
Furthermore there is a splice variant of IL-4, known as IL-4δ2 [14].  This is a natural antagonist 
of IL-4.  During treatment the mRNA for IL-4 decreases, whereas the IL-4δ2 mRNA increases 
(Dheda, K. et al, unpublished results).  Still more revealing is the observation that expression of 
IL-4δ2 mRNA is increased in the peripheral blood of healthy donors who have latent TB, as 
defined by the presence of a positive ELISPOT IFN-γ response to ESAT-6.  This has been shown 
by different methods in Ethiopia and in The Gambia [18, 19].  It implies that despite their healthy 
appearance, people with latent TB are involved in a “battle” between IL-4 and its inhibitor.  We 
have hypothesised that this IL-4/IL-4δ2 ratio might be a factor that determines whether latent TB 
progresses or remains latent [6]. The detrimental effects of IL-4 listed above might be blocked if 
there is sufficient expression of IL-4δ2, allowing expression of iNOS that the organisms into the 
latent state. 
 
3. The hypothesis and its implications 
3.1.  The importance of the mixed Th1/IL4 response to M. tuberculosis 
The overall hypothesis is that despite rapid induction of a dominant Th1 response, M. 
tuberculosis may evoke a minor IL-4 response that is sufficient in some individuals to undermine 
the efficacy of Th1-mediated immunity and cause immunopathology [6]. The recent discovery 
that the virulent Beijing strains cause human monocytes to express IL-4 and IL-13 is compatible 
with this [20]. However this simple concept has other implications, and can resolve several 6 
outstanding paradoxes. We suggest that M. tuberculosis exploits and enhances a pre-existing Th2 
component that exists in citizens of developing countries. 
 
3.2. Failure of BCG vaccination in developing countries 
It has been known for decades that the efficacy of BCG vaccination varies in different parts of the 
world. In general it is least effective in developing countries where it is most needed [21].  There 
has been no universally accepted explanation for this phenomenon. However in these countries 
there is a background of Th2 response to some components of M. tuberculosis. This was clearly 
demonstrated in blood samples from Malawians in which PPD induced IL-5 secretion, whereas 
little IL-5 was seen in samples from the UK run in parallel (Dockrell, H., personal 
communication). Worse still, BCG vaccination failed to down-regulate the IL-5 response 
(Dockrell, H., personal communication).  This Th2 activity might be attributable to the exposure 
of mother and child to helminths.  BCG induced a Th2-biased response in babies that had been 
sensitised in utero to antigens of Wuchereria bancrofti or Schistosoma haematobium because 
their mothers were suffering from these infections [22]. Presumably contact with cross-reactive 
environmental mycobacteria would do the same thing in these babies. However these organisms 
also induce a Th1 response in Malawi that is demonstrably protective [23], and the possible 
interplay between the Th1 and Th2 components is crucial, and is discussed later. 
 
3.3 Discordant result of attempts to measure IL-4 in tuberculosis cases from developed and 
developing countries 
The levels of IL-4 detected in tuberculosis patients, or released by their lymphocytes when 
stimulated with mycobacterial antigen in vitro, differ markedly in different studies. At one 
extreme, free IL-4 may be detected easily by ELISA in the patients’ serum or in supernatants of 
patients’ peripheral blood mononuclear cells cultured with tuberculosis antigen in vitro (see 
Table).  At the other extreme IL-4 is not detected at all, or only using sensitive quantitative RT-
PCR, or by flow cytometry after stimulating the cells in the presence of   PMA, calcium 
ionophore and an inhibitor of cytokine export.  Interestingly the studies that require the very 
sensitive methods are those based in Europe or the United States.  In contrast, the studies where 
IL-4 was readily detected by ELISA in serum or in cell culture supernatants, tend to have taken 
place in developing countries. These points are illustrated in Fig 1, and the source of the 
information is listed in the table. Clearly some of the patients studied in Europe or the USA will 7 
themselves have come initially from developing countries, but the distinction remains in the 
examples we have found, despite this potential dilution of the difference between the two 
environments. 
 
3.4. High fatality rates early during treatment in patients in developing countries. 
Death rates from tuberculosis during the first 2 months of treatment are said to be unusually high 
in many developing countries. If this is true (but see below), it is intriguing to speculate that in 
patients with a significant background of Th2 response to M. tuberculosis, release of antigen 
during therapy leads to a systemic Koch phenomenon mediated by IL-4 and TNF-α as outlined 
earlier.  For instance a high mortality is claimed in Malawi [24], where a background of Th2 
response to M. tuberculosis has been documented. However there is also a high rate of HIV in 
this country. Other confounding factors that affect death rates include distance from health care 
centres, and the severity of the disease at the time of diagnosis.  Nevertheless death rates from 
tuberculosis are probably high in some developing countries even when these factors are taken 
into account [25, 26]. In an area of rural South Africa, with a TB control programme and low 
sero-prevalence rates for HIV, the mortality in those diagnosed with tuberculosis was 13% [25]. 
Further studies will be needed to test the hypothesis that there are more deaths in developing 
countries, due to a systemic Koch phenomenon aggravated by IL-4.  
 
3.5. Discordant doses of M. tuberculosis required to infect mice in developed and developing 
countries. 
Another striking difference between some developing countries and the USA, is the dose of M. 
tuberculosis required to establish pulmonary infection in mice.  Authors in the USA routinely 
establish infection using aerosols that deliver 100-200 bacteria to the lungs.  This may be an 
underestimate, and many of the bacilli delivered this way will go to the gastrointestinal tract, so 
there may be complex immunological events that are ignored. Nevertheless this observation is 
incompatible with the fact that in Mexico City the same strain of M. tuberculosis, in the same 
inbred mouse strain, will not establish progressive infection at an intratracheal dose of less 
than10
6 bacilli. In fact even a dose as high as 4000 organisms leads to latent non-progressive 
disease in Mexico City, detectable only by in situ PCR [27]. We suggest that contact with 
environmental saprophytes in animal facilities in developing countries induces a mixed Th1/Th2 
response (mostly Th1), such as that seen in the human population of Malawi [23] and (Dockrell, 8 
H., personal communication). A low dose infection may be dealt with by the dominant Th1 
component. But particulate antigens such as Leishmania [28] or mycobacteria [5] tend to evoke 
Th2 responses at higher doses. So when a high dose infection is given, there is a greater 
probability that the Th1 response will be undermined by the activation of the pre-existing Th2 
component.  
 
We suggest that mycobacteria- naïve citizens of the USA resemble the immunologically naïve 
mice in a modern animal facility, and 5% or so will develop infection following exposure to 
relatively low doses of M. tuberculosis, with little induction of IL-4. In contrast, the citizens of 
developing countries rich in mycobacteria and helminths have pre-existing Th1 and Th2 
responses induced by these organisms.  Under these conditions a high dose of M. tuberculosis is 
required for infection, which only progresses in those people in whom the TB is able to exploit 
the pre-existing Th2 component, and so induce an IL-4 response that is large enough to 
undermine the pre-existing Th1. Beijing strains should be particularly good at this [20]. In some 
individuals, for reasons that we do not yet understand, the effect of the IL-4 will be blocked by a 
disproportionate rise in IL-4δ2 [18, 19]. 
 
4. Implications for vaccine design 
The evidence reviewed here suggests that the current studies of Th1-inducing vaccine candidates 
will fail to reveal anything that can improve on BCG. Induction of Th1 responses may not be 
relevant, since M. tuberculosis rapidly does this anyway. Furthermore, in experimental animals, 
manipulations that increase the Th1 response still further than is achieved by BCG vaccine alone, 
do not provide any additional protection [29, 30]. Enough Th1 is enough. Any further protection 
requires something else. It might be more important to devise vaccines that switch off the 
“subversive” Th2 component probably always present in developing countries.  This is entirely 
feasible.  Ways of switching off pre-existing Th2 responses by inducing appropriate types of 
regulatory T cell have been discovered in studies of allergic disorders, where much larger Th2 
responses have been targeted [31]. This regulatory approach to vaccine design will be particularly 
relevant to therapeutic vaccination. Th1-inducing vaccines make ongoing disease worse [32, 33]. 
In other words they evoke local and distant Koch phenomena. (The findings of Robert Koch in 
the 1890’s are rediscovered at regular intervals). Interestingly the only vaccine candidates shown 
to be effective therapeutically in the Balb/c mouse TB model both work at least in part by 9 
suppressing the IL-4 response [34, 35], which BCG, studied in parallel, failed to do [35]. In 
conclusion the time may have come for a radical reappraisal of the thinking behind the current 
wave of “rationally” designed vaccine candidates. 
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Geographical distribution of tuberculosis patients in whom IL-4 production was massively 
increased (i.e. detectable by simple ELISA assay or equivalent method) (black triangles) or 
required RT-PCR or prestimulation and flow cytometry (red circles). The location of the sites, 
and the references, are listed in the Table. The dashed lines are drawn at approximately 30º North 
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